VUNO, Inc.

Based in South Korea, VUNO, Inc. specializes in developing advanced artificial intelligence medical solutions to improve healthcare delivery and diagnostic accuracy. VUNO, Inc. is engaged in creating AI-driven healthcare products and was founded in 2014 in Seoul, South Korea.

The company has secured a total of KRW 37. 8 billion in an IPO on February 26, 2021, and has successfully completed 7 deals. The founders, Mauricio Cardoso and Ricardo Bonfá, alongside CEO Yeha Lee, have positioned the company for growth in the health tech space. VUNO Inc.

specializes in the development and provision of artificial intelligence-based medical solutions aimed at enhancing healthcare delivery and diagnostic accuracy. The company's core product offerings include VUNO Med solutions such as Chest X-ray, BoneAge, Fundus AI, DeepBrain, LungCT AI, DeepASR, and DeepCARS. Each of these products serves unique functions: for instance, VUNO Med-Chest X-ray analyzes chest X-ray images to identify abnormal findings and their locations, while VUNO Med-Fundus AI assesses retinal images for various eye conditions. These products are designed to integrate seamlessly into clinicians' workflows, providing tools for the early detection and management of chronic diseases, neurological disorders, and other health concerns.

VUNO's clientele primarily consists of healthcare professionals and institutions, including hospitals and clinics, operating in various geographical markets, notably South Korea and potentially expanding into other regions requiring advanced diagnostic solutions. In 2024, VUNO Inc. reported a revenue of KRW 18,979,814. 20 and an EBITDA of KRW -8,012,368.

70. The company generates revenue through the sale of its AI-driven medical products and services to healthcare providers, primarily through a direct-to-consumer model. Partnerships with hospitals and clinics that utilize its proprietary technologies enhance diagnostic capabilities and patient care. Revenue is derived from the licensing of its flagship products, such as VUNO Med-Chest X-ray and VUNO Care-Hativ, which may be offered under subscription models or as one-time purchases, depending on the client's needs.

VUNO Inc. plans to leverage its recent IPO funding of KRW 37. 8 billion to enhance its product offerings and expand into new markets. Upcoming products are under development, with a focus on further integrating AI technology into healthcare solutions.

Specific target markets for expansion include other regions in Asia and beyond, with plans to initiate this growth strategy by 2025.